Dechert advised Sofinnova Partners, a leading European venture capital firm specialized in life sciences, as part of its €10 million Series A financing in AblaCare, a medical device company specializing in female fertility, to bring its device for treating polycystic ovary syndrome to the market.
This investment will allow the project to enter the clinical phase with a view to obtaining CE marking in 2020.
Dechert's team of lawyers was led by Anne-Charlotte Rivière; partner, and Anaïs Roudel, associate.
About Dechert
Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
